Introduction: Lymphovascular invasion (LVI) is a histopathological feature that is associated with an increased risk for micrometastasis. The aim of this study was to determine the prognostic and staging value of LVI among patients with esophageal squamous cell carcinoma (ESCC) undergoing esophagectomy.
Introduction
Multidisciplinary therapies have been demonstrated to improve the prognosis of some esophageal carcinoma subgroups, [1] [2] [3] [4] [5] and accurate prognostication and staging assessment are essential to tailoring an optimal multidisciplinary treatment. Although the seventh edition of the American Joint Committee on Cancer (AJCC) TNM staging system for esophageal carcinoma 6 has better performance in prognostication than the previous edition, 7, 8 there is still space for improvement, especially for T2-3N0M0 disease. [9] [10] [11] [12] Additional modifications still need to be proposed with improvement in the understanding of cancer biology.
Histopathological examination is the most practical and inexpensive method for the investigation of tumor behavior, particularly in comparison with molecular methods. Lymphovascular invasion (LVI) is a histopathological feature that is associated with biologically aggressive disease, and it can be easily and reliably evaluated using routine light microscopic examination. Indeed, LVI is an essential and important step in lymph node metastasis and systemic dissemination of cancer cells, and it is considered to increase the risk for micrometastases in localized carcinoma. 13 The unfavorable prognostic significance of LVI has been supported by studies involving solid tumors, such as breast carcinoma, 14, 15 lung carcinoma, 16, 17 and bladder carcinoma. 18 However, the role of LVI as a predictor of survival in esophageal squamous cell carcinoma (ESCC) has not been adequately investigated. Previous single-institutional studies have habitually been limited by small sample sizes as well as heterogeneity of tumor stages, histological subtypes, multidisciplinary treatment regimens, and adequacy of surgical resection, resulting in controversial conclusions. [19] [20] [21] [22] [23] [24] [25] [26] Herein, we conducted a cohort study to evaluate the impact of LVI on survival and to determine the role of LVI in ESCC staging, which were validated internally using 1000-bootstrap resamples and externally in four independent databases.
Methods

Study Population
An esophageal carcinoma database that was prospectively maintained by the Guangdong Esophageal Cancer Institute from January 1999 to December 2006 was retrospectively analyzed, and 1458 consecutive cases from Sun Yat-Sen University Cancer Center (Guangzhou, China) were enrolled. The database recorded information regarding sociodemographic data, disease extent, treatment administered, and follow-up status. The patients included in the current study fulfilled the following criteria: (1) histologically confirmed thoracic ESCC, (2) receipt of complete resection and regular follow-up, (3) no distant metastasis, (4) no previous malignant disease or second primary tumor, (5) no previous anticancer treatment or adjuvant treatment, (6) availability of qualified surgical specimens, and (7) age between 18 and 80 years. A total of 666 patients were eligible for our analysis according to the inclusion criteria (see Supplementary Fig. 1 ). The external validation cohort was composed of 795 patients from Sun Yat-Sen University Cancer Center (Guangzhou, Guangdong Province, People's Republic of China), Cancer Hospital of Shantou University Medical College (Shantou, Guangdong Province, People's Republic of China), Fujian Medical University Union Hospital (Fuzhou, Fujian Province, People's Republic of China), and Taizhou Hospital (Taizhou, Zhejiang Province, People's Republic of China) who were treated between January 2011 and December 2011. With the same criteria as just listed, 222 node-negative patients were included, and their samples were reevaluated by pathologist J. T. Jin. The pathological stage of every case was reevaluated according to the seventh edition of the AJCC staging system for esophageal carcinoma. 6 The institutional review board at each participating center approved the analysis of the anonymous data.
The preoperative workup was conducted as previously described 27 to confirm that patients were clinically fit for surgery. The surgical procedure included both right and left transthoracic esophagectomy. Only some tumors of the lower and middle sections of the thoracic esophagus received a left transthoracic esophagectomy with a longitudinal resection margin more than 5 cm from the tumor. 28 The tumor-bearing esophagus was resected en bloc together with the adjoining connective tissues. At least a two-field lymph node dissection, including standard, extended, or total dissection of the thoracic and abdominal lymph nodes, was performed in all patients.
Pathological Evaluation
All specimens were processed according to institutional protocols. In brief, the gross specimens and lymph nodes were collected in the specimen room by surgeons. Samples were fixed in 10% neutral buffered formalin immediately after collection and subsequently embedded in paraffin. Serial sections were stained with hematoxylin and eosin (HE). After careful selection, the four most typical HE-stained slides and the paraffin blocks were stored in the archive room.
LVI was defined as the presence of tumor cells within an endothelium-lined space without underlying muscular walls. 13, 18 All slides were reassessed by three independent and experienced pathologists (J.T. Jin, MD, C. Zhang, MD, PhD, and Y.H. Ling, MD) from the Esophageal Carcinoma Pathology Group, who had all evaluated the LVI status of more than 200 cases. They were all blinded to the clinical data. Immunohistochemical (IHC) staining for endothelial cells was not performed routinely in keeping with standard pathology practice. Each pathologist achieved agreement regarding LVI between the HE-stained and immunohistochemically stained slides in more than 88% of cases from an independent cohort of 50 patients. These results indicated that the evaluation of LVI using HE-stained slides was reliable. No attempt was made to differentiate between vascular and lymphatic vessels because of the difficulty involved and lack of reproducibility when undertaking routine light microscopic examination. The three pathologists worked collaboratively to reach a consensus in equivocal cases. If that approach failed, additional IHC staining was carried out. Gross pathology reports were also reviewed, and two patients who were missed in the reassessment of the slides were determined to be LVI positive.
Follow-Up
The patients were followed up every 3 months for the first 2 years, then every 6 months for the following 3 years, and finally annually. The diagnostic examinations consisted of a barium swallow, chest radiography, esophagoscopy, computed tomography, abdominal ultrasonography, and bone scan when necessary for the detection of recurrence and/or metastasis. The followup was performed by the oncologic outpatient clinic or by official telephone contact with patients or their relatives. The final follow-up date was March 31, 2014 , and the median follow-up time was 114.9 months (range 0.5-178).
The primary end point was disease-specific survival (DSS), which was calculated from the date of surgery to the date of death from esophageal carcinoma. The secondary end point was disease-free survival (DFS), which was calculated from the date of surgery to the date of first recurrence or metastasis of cancer or to the date of death. Recurrent disease (either local or distant) was histologically confirmed whenever possible.
Statistical Analysis
The categorical variables between the LVI-positive and LVI-negative groups were compared using the c 2 test. Survival curve was depicted using Kaplan-Meier method and compared using the log-rank test. All variables that attained a significance level of p < 0.10 in a univariate analysis were included in the multivariate Cox proportional hazard regression analysis; Cox regression coefficients were used to generate risk score models. Internal validation was carried out by means of 1000-bootstrap resampling, which made efficient use of all the data and avoided overfitting. The predictive accuracy of the different models was evaluated using timedependent receiver operating characteristic (ROC) curves (Kaplan-Meier method), 29, 30 which plotted the time-dependent area under the curve for different values of the follow-up time and was quantified using the Cindex, 31, 32 which was compared with the results of the Mantel-Haenszel test. Time-dependent ROC analysis and the C-index are especially applicable for time-to-event outcomes in predictive discrimination. Statistical significance was set at p < 0.05 and all tests were two sided. Statistical analyses were carried out using SPSS 22.0 software for Windows (SPSS Inc., Chicago, IL). Timedependent ROC analysis and calculation of the C-index were undertaken using R software version 3.1.0 with the risksetROC and survcomp package. 33 
Results
Basic Characteristics of the Study Population
In total, LVI was present in 33.8% of patients (225 of 666), involving 21.5% (75 of 349) and 47.3% (150 of 317) of node-negative and node-positive patients, respectively. The rate of LVI increased significantly with advanced T and N classifications (Table 1) .
LVI and Clinical Outcomes in the Primary Cohort
The overall 5-and 10-year DSS rates were 41.0% and 32.9%, respectively. The overall 5-and 10-year DFS rates were 36.8% and 30.6%, respectively. The 5-year DSS rate was significantly lower in patients with LVI than in patients without LVI (24.8% versus 48.9%, logrank p < 0.001 [ Fig. 1A]) ; this was also true of the 5-year DFS rate (20.3% versus 47.7%, log-rank p < 0.001 [ Fig. 1B]) .
In a univariate analysis, sex, age, weight loss, smoking status, alcohol consumption status, pT classification, pN classification, tumor length, LVI, and perineural invasion were predictors of survival (all p < 0.10 [see Supplementary Table 1] ). In the multivariate Cox regression analysis adjusted for these covariates, LVI was found to be an independent predictive factor for unfavorable prognosis with regard to both DSS (hazard ratio ¼ 1.59, 95% confidence interval: 1.30-1.94) and DFS (hazard ratio ¼ 1.62, 95% confidence interval: 1.32-1.98) ( Table 2) .
When stratified using clinicopathological risk factors, LVI remained a clinically and statistically significant predictive factor for adverse prognosis, except in the N1 (log-rank p ¼ 0.052) and N2þ3 (log-rank p ¼ 0.17) subsets (see Supplementary Fig. 2 ).
Subgroup Analysis according to Nodal Status
Of 349 node-negative patients, 75 (21.5%) presented with LVI, and the presence of LVI strongly predicted an inferior DSS rate (log-rank p < 0.001 [ Fig. 1C]) . In the multivariate analysis adjusted for sex, age, weight loss, smoking status, alcohol consumption status, pT classification, and perineural invasion, LVI and pT classification were found to be independent predictors of DSS and DFS (all p < 0.001) ( Table 3) . Bootstrapping with 1000 replicates was applied for the internal validation, and the results showed a very high consistency (see Supplementary Table 2) .
Of the 317 node-positive patients, 150 (47.3%) presented with LVI. In a univariate analysis, LVI was associated with poorer DSS (log-rank p ¼ 0.013 [ Fig. 1D] ) and DFS (log-rank p ¼ 0.028); however, this association with poorer DSS and DFS was not observed in the multivariate analysis (for DSS, p ¼ 0.081; for DFS, p ¼ 0.094 [see Supplementary Table 3] ). Internal validation (see Supplementary Table 4 ) further confirmed that the negative results in the node-positive subgroup were not due to chance.
LVI Improved the Predictive Accuracy
The predictive accuracy of prognosis of LVI and the TNM system (T/N/G/location classification) was evaluated using time-dependent ROC curves and quantified by means of the C-index (see the Supplementary Materials, page 1). The area under the curve for the LVI and T classification combination model stably predicted DSS times up to and including 120 months for node-negative patients with ESCC, which was greater than when the TNM system and other factors were used alone ( Fig. 2A) . Compared with the TNM system, the LVI and T classification combination model significantly improved the Cindex in predicting DSS and DFS (gains in C-index of 3.5% and 4.8%, respectively, both p < 0.001 [see Supplementary Table 5] ). The addition of LVI even 
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decreased the predictive accuracies of the TNM system for DSS and DFS (declines in the C-index of 1.5% and 2.5%, respectively).
External Validation
External validation was conducted using the fourcenter database, which included 222 node-negative patients, 17.6% (39 of 222) of whom presented with LVI (see Table 1 ). The 3-year DSS rates were 85.3% and 63.3% for LVI-negative and LVI-positive patients, respectively (log-rank p ¼ 0.003 [see Supplementary  Fig. 3]) . LVI remained an independent predictor for DSS in the multivariate analysis (p < 0.001 [see Table 3 ]). The predictive accuracy of prognosis of the LVI and T classification combination model for DSS remained higher than that of the TNM system with regard to the time-dependent ROC curves (Fig. 2B) and was quantified by a gain of 3.9% in the C-index (p < 0.001 [see Supplementary Table 5] ).
Node-Negative Patients with LVI Might Be Upstaged
The primary and validation cohorts were combined into an entire cohort to explore how LVI should be integrated into the TNM system. Of 396 patients with T2-3N0M0 disease, which was staged according to tumor location and grade, the 5-year DSS for the IB, IIA, and IIB groups were 62.3%, 56.4%, and 50.8%, respectively (log-rank p ¼ 0.73 [ Fig. 3A] ). In contrast, the 5-year DSS of T2N0M0 disease with LVI was significantly lower than that of T2N0M0 disease without LVI (33.8% versus 65.1%, log-rank p ¼ 0.03) and similar to that of T2N1M0 disease (32.1%, log-rank p¼0.50 [ Fig. 3B]) . Analysis of patients with T3N0-1M0 and T1N0-1M0 disease gave similar results (Figs. 3C and D) . These data indicated that node-negative patients with LVI might be considered for upstaging as N1 disease in pathological staging.
Discussion
In this large-scale database of patients undergoing esophagectomy alone, we found that 33.8% of patients had LVI, which is in accordance to previous studies, in which the rates varied from 27% to 39%. [19] [20] [21] 24, 25 LVI was associated with the established features of biologically aggressive ESCC, such as high tumor stage and metastases to lymph nodes. LVI was found to be an independent predictor of DSS and DFS only among nodenegative patients, which was internally validated by 1000-bootstrap resamples. The combination of LVI and the TNM system significantly improved the predictive accuracy of prognosis; this was externally validated in a multicenter database. Furthermore, the similar survival between node-negative patients with LVI and pN1 disease supports the hypothesis that LVI precedes or occurs concurrently with lymph node metastasis. Once nodes are involved, LVI no longer independently predicts survival. The prognostic and staging value of LVI among localized disease seems to be related to the ability to identify patients at high risk for micrometastases or false-negative nodal status. Controversy exists among several single-institutional studies concerning the relationship between LVI and the survival of patients ESCC who undergo esophagectomy. Brucher et al. 19 and Zhu et al. 26 proposed that LVI was an indicator of adverse prognosis independent of clinicopathological factors. However, these findings had not been consistently observed in other studies. 22, 24, 25 Indeed, the composition of the patient populations enrolled in these previous cohorts varied from study to study; they included patients with both ESCC and esophageal adenocarcinoma who had undergone surgery alone or received adjuvant therapies after surgery. In addition, some previous studies have even included distant metastatic tumors. Hence, we conducted the current large-scale prospective cohort study and validated the prognostic and predictive value of LVI in a multicenter database. We attempted to decrease selection biases by reporting on a relatively homogeneously treated cohort, which consisted only of patients with ESCC without distant metastasis. To our knowledge, the present study is the first to have performed detailed subgroup analysis according to clinicopathological parameters. Our subgroup analysis revealed that the effect of LVI on survival existed only in the node-negative subgroup, which is in agreement with studies involving other solid tumors, 13, 14, 17, 18 which may explain the contradictory results of previous studies.
The TNM staging system has continually been modified to accurately stratify cancer prognosis. The introduction of tumor location and grade into the staging system for T2-3N0M0 disease is one of the most debatable alterations to the seventh edition of the TNM staging system for ESCC. Like previous studies, 8, 10, 12, 34 the current staging system failed to stratify the survival of patients with T2-3N0M0 disease in our cohort. In contrast, LVI status could significantly distinguish the prognosis of T1N0M0, T2N0M0, and T3N0M0 disease, and LVI-positive patients had a similar prognosis with pN1 disease. Moreover, the C-index of the LVI and T classification combination model for predicting survival was significantly higher than that of the TNM model, both in the node-negative subset of the primary cohort and in the validation cohort. LVI has already been included in the TNM staging systems for some malignancies. 35 According to the AJCC Cancer Staging Manual (seventh edition), tumor deposits, which are considered to present discontinuous spread or vascular invasion, are classified as N1c in colorectal cancer. Similarly, upstaging value of LVI was demonstrated in our cohort with ESCC. Our results strongly suggest that LVI might be considered for inclusion in the staging system for ESCC. International prospective studies are needed to further confirm our results.
The optimal management of patients with early-stage esophageal carcinoma has not been definitively established. 36 Approximately 30% to 60% of node-negative patients experienced a fatal recurrence within 5 years Figure 2 . Time-dependent receiver operating characteristic analysis. The area under the curve for the risk score involving the combination of lymphovascular invasion status and the T classification remained higher than those for the tumor, node, and metastasis system and other factors alone among node-negative patients in the primary cohort (A) and the validation cohort (B). LVI, lymphovascular invasion; TNM, tumor, node, and metastasis; T, tumor.
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LVI as Prognostic, Staging and Factor in ESCCafter surgery alone, 6 indicating that local treatment might be insufficient. As a promising method for improving outcomes, multidisciplinary treatment might nevertheless add serious adverse events in addition to the significant survival benefit to early-stage patients in clinical trials. 5, 37 The identification of patients with node-negative ESCC who are at high risk for disease recurrence and are likely to benefit from adjuvant therapy remains of great importance and a clinical challenge. The presence of LVI in primary tumors would imply the incidence of micrometastases or false-negative nodal status, resulting in worse prognosis. 13 This is very important because the JCOG 9204 trial 5 demonstrated that patients with lymph node metastasis were able to benefit from postoperative adjuvant chemotherapy. Adjuvant therapy might be indicated for patients with early ESCC involving LVI might. On the basis of LVI status, selective adjuvant therapy might be conducted to avoid unnecessary severe adverse events in overtreated patients. Well-designed prospective clinical trials might be warranted to identify whether the presence of LVI could be used as a trigger for adjuvant treatment in early ESCC.
A great advantage of LVI as a prognostic factor is that it can be accurately assessed in routinely processed paraffin-embedded, HE-stained slides through routine light microscopy. We classified lymphatic and blood vessel invasion as LVI, which is in agreement with the U.K. and U.S. guidelines. 14 The criteria used are simple and do not necessitate expensive IHC stains that might delay the reporting of the results. 
